Display options
Cite
Botticelli A, Mazzuca F, Borro M, et al. FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. World J Oncol. 2015;6(5):437-440doi: 10.14740/wjon934w.
Botticelli, A., Mazzuca, F., Borro, M., Mazzotti, E., La Torre, M., Bonifacino, A., Ciabatta, F. R., Gentile, G., Maddalena, C., Simmaco, M., & Marchetti, P. (2015). FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. World journal of oncology, 6(5), 437-440. https://doi.org/10.14740/wjon934w
Botticelli, Andrea, et al. "FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?." World journal of oncology vol. 6,5 (2015): 437-440. doi: https://doi.org/10.14740/wjon934w
Botticelli A, Mazzuca F, Borro M, Mazzotti E, La Torre M, Bonifacino A, Ciabatta FR, Gentile G, Maddalena C, Simmaco M, Marchetti P. FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26. PMID: 28983344; PMCID: PMC5624668.
Copy Download .nbib Format: NLM
Share it on

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?.

World journal of oncology

Andrea Botticelli, Federica Mazzuca, Marina Borro, Eva Mazzotti, Marco La Torre, Adriana Bonifacino, Francesca Romana Ciabatta, Giovanna Gentile, Chiara Maddalena, Maurizio Simmaco, Paolo Marchetti

Affiliations

  1. Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
  2. Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome - Advanced Molecular Diagnostics Unit (DiMA), Sant'Andrea Hospital, Rome, Italy.
  3. Department of General Surgery, Sant'Andrea Hospital, Rome, Italy.

PMID: 28983344 PMCID: PMC5624668 DOI: 10.14740/wjon934w

Abstract

BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients.

METHODS: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed.

RESULTS: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012).

CONCLUSIONS: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.

Keywords: Breast cancer; FCGR; Polymorphisms; Trastuzumab

References

  1. Ann Oncol. 2011 Jun;22(6):1302-7 - PubMed
  2. Blood. 1990 Dec 15;76(12):2421-38 - PubMed
  3. J Clin Invest. 1992 Oct;90(4):1537-46 - PubMed
  4. Oncology. 2012;83(4):218-27 - PubMed
  5. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 - PubMed
  6. Blood. 1997 Aug 1;90(3):1109-14 - PubMed
  7. Nat Med. 2000 Apr;6(4):443-6 - PubMed
  8. Eur J Immunol. 2001 Oct;31(10):3016-25 - PubMed
  9. J Biol Chem. 2001 Mar 2;276(9):6591-604 - PubMed
  10. J Immunol. 2011 Mar 15;186(6):3401-9 - PubMed
  11. Scand J Immunol. 2012 Aug;76(2):167-74 - PubMed
  12. J Immunol. 1991 Aug 15;147(4):1338-43 - PubMed
  13. Nat Rev Drug Discov. 2012 Mar 30;11(4):311-31 - PubMed
  14. Br J Cancer. 2006 Jan 30;94(2):259-67 - PubMed
  15. J Clin Oncol. 2008 Apr 10;26(11):1789-96 - PubMed
  16. J Clin Invest. 1992 Apr;89(4):1274-81 - PubMed
  17. J Hematol Oncol. 2013 Jan 04;6:1 - PubMed
  18. Clin Cancer Res. 2012 Jun 15;18(12):3478-86 - PubMed

Publication Types